This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yamagami, K. Articles by Sasaki, T. Search for Related Content PubMed PubMed Citation Articles by Yamagami, K. Articles by Sasaki, T.

Antitumor Activity of 2'-Deoxy-2'-methylidenecytidine, a New 2'-Deoxycytidine Derivative

Research Laboratories, Yoshitomi Pharmaceutical Industries, Ltd., 3-7-25 Koyata, Iruma-shi, Saitama 358 [K. Y., A. F., M. A., T. O.]; Research Laboratories, Yamasa Shoyu Co., Ltd., 2-10-1 Araoi-cho, Choshi-shi, Chiba 288 [S. S.]; Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo 060 [A. M., T. U.]; and Cancer Research Institute, Kanazawa University, Takara-machi, Kanazawa 920 [T. S.], Japan

The antitumor activity of 2'-deoxy-2'-methylidenecytidine (DMDC), an inhibitor of DNA synthesis, was examined and compared with that of 1-ß-D-arabinofuranosylcytosine (ara-C) against various murine tumors and human tumor xenografts. Against P388 murine leukemia, repeated treatments of DMDC were more effective than its single administration. Interestingly, DMDC was effective against colon 26 murine carcinoma, M5076 murine reticulum cell sarcoma, LX-1 human lung cancer xenograft, and SK-Mel-28 human melanoma xenograft, which are less sensitive or refractory to ara-C, while DMDC was not more potent against murine leukemias P388 and L1210 than ara-C. The in vitro cytotoxic effects of DMDC and ara-C against L1210 leukemia cells were prevented dose dependently by deoxycytidine, suggesting that DMDC, like ara-C, may require phosphorylation by deoxycytidine kinase for antitumor activity.

DMDC was effective against human and murine experimental tumor models, especially nonleukemic tumors refractory to ara-C, suggesting that DMDC will be a promising agent for the treatment of cancer.

¹ To whom requests for reprints should be addressed.

Received 11/19/90. Accepted 2/22/91.

This article has been cited by other articles:

				N. Niitsu, Y. Ishii, A. Matsuda, and Y. Honma Induction of Differentiation of Acute Promyelocytic Leukemia Cells by a Cytidine Deaminase-resistant Analogue of 1-{beta}-D-Arabinofuranosylcytosine, 1-(2-Deoxy-2-methylene-{beta}-D-erythro-pentofuranosyl)cytidine Cancer Res., January 1, 2001; 61(1): 178 - 185. [Abstract] [Full Text]

				N. Masuda, K. Matsui, N. Yamamoto, T. Nogami, K. Nakagawa, S. Negoro, K. Takeda, N. Takifuji, M. Yamada, S. Kudoh, et al. Phase I Trial of Oral 2'-Deoxy-2'-methylidenecytidine: On a Daily 14-day Schedule Clin. Cancer Res., June 1, 2000; 6(6): 2288 - 2294. [Abstract] [Full Text]